Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Background: Recent attention has focused on understanding the role of the brain-renin-angiotensin-system (RAS) in stroke and neurodegenerative diseases. Direct evidence of a role for the brain-RAS in Parkinson's disease (PD) comes from studies demonstrating the neuroprotective effect of RAS inhibitors in several neurotoxin based PD models. In this study, we show that an antagonist of the angiotensin II (Ang II) type 1 (AT 1) receptor, losartan, protects dopaminergic (DA) neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity both in primary ventral mesencephalic (VM) cultures as well as in the substantia nigra pars compacta (SNpc) of C57BL/6 mice (Fig. 1). Results: In the presence of exogenous Ang II, losartan reduced MPP+(5 μM) induced DA neuronal loss by 72%in vitro. Mice challenged with MPTP showed a 62% reduction in the number of DA neurons in the SNpc and a 71% decrease in tyrosine hydroxylase (TH) immunostaining of the striatum, whereas daily treatment with losartan lessened MPTP-induced loss of DA neurons to 25% and reduced the decrease in striatal TH+immunostaining to 34% of control. Conclusion: Our study demonstrates that the brain-RAS plays an important neuroprotective role in the MPTP model of PD and points to AT 1 receptor as a potential novel target for neuroprotection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · cited 1×
“Insights into the mechanisms responsible for PD have come from epidemiological studies and through animal models of DA neurodegeneration [3-5].”
BackgroundChronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683 · cited 1×
“Treatment of rodents and non-human primates with neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine [6,7] and rotenone [8] have helped us understand that oxidative stress, mitochondrial respiration dysfunction and protein aggregation are primary mediators of the dopaminergic neu…”
BackgroundWest, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994 · cited 1×
“THimmunoreactive SNpc neurons were estimated using an unbiased stereological method according to the optical fractionator principle [59-61] using a Leica DMRB microscope with motorized stage running BioQuant Nova Prime Revision 3.”
MethodInternational Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663 · cited 1×
“Treatment of rodents and non-human primates with neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine [6,7] and rotenone [8] have helped us understand that oxidative stress, mitochondrial respiration dysfunction and protein aggregation are primary mediators of the dopaminergic neu…”
BackgroundGundersen, H. J. G. (1986) · PubMed · Cited by 1,658
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
DOPAMINE (3-HYDROXYTYRAMINE) AND BRAIN FUNCTION
HORNYKIEWICZ, O. (1966) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07154-6 · Cited by 1,442 · cited 1×
“There is now clear evidence showing that the primary pathological feature of PD is the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) [2].”
BackgroundGundersen, H. J. G. (1986) · Journal of Microscopy · doi:10.1111/j.1365-2818.1986.tb02764.x · Cited by 1,429
Functions of Angiotensin in the Central Nervous System
Phillips, I. M. (1987) · Annual Review of Physiology · doi:10.1146/annurev.ph.49.030187.002213 · Cited by 742 · cited 1×
“The renin-angiotensin system is best known for its role in regulating blood pressure, activation of sympathetic pathways, stimulation of vasopressin release, regulating drinking behavior and cerebral blood flow [11,12].”
BackgroundSingh, K. D., & Karnik, S. S. (2020) · GPCRs · doi:10.1016/b978-0-12-816228-6.00020-9 · Cited by 704
Przedborski, S., Jackson-Lewis, V, Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624
Systematic review of incidence studies of Parkinson's disease
Twelves, D., Perkins, K. S. M., & Counsell, C. (2003) · Movement Disorders · doi:10.1002/mds.10305 · Cited by 622 · cited 1×
“Insights into the mechanisms responsible for PD have come from epidemiological studies and through animal models of DA neurodegeneration [3-5].”
BackgroundPetrova, P. S., Raibekas, A., Pevsner, J., Vigo, N., Anafi, M., Moore, M. K., Peaire, A. E., Shridhar, V., Smith, D. I., Kelly, J., et al. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:2:173 · Cited by 352 · cited 1×
“In support of the indirect theory, astrocytes are known to produce factors such as glial cell line-derived neurotrophic factor (GDNF) and mesencephalic astrocytes-derived neurotrophic factor (MANF), two highly potent neurotrophic factors for DA neurons [40,41].”
BackgroundHemming, M. L., & Selkoe, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 332 · cited 1×
“While we are actively investigating the role of the brain-RAS in PD, the angiotensin system may have a role in other neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, and Huntington's disease [22,48].”
BackgroundLevels of angiotensin and molecular biology of the tissue renin angiotensin systems
Ian Phillips, M., Speakman, E. A., & Kimura, B. (1993) · Regulatory Peptides · doi:10.1016/0167-0115(93)90403-u · Cited by 329 · cited 1×
“Only recently has it been discovered that all the required components of the RAS, such as renin, angiotensinogen, angiotensin converting enzyme (ACE), angiotensin II (Ang II) and the Ang II (AT) receptors, are present in the mammalian brain [13,14].”
BackgroundPrzedborski, S., & Vila, M. (2003) · PubMed · Cited by 286
Comparative cytoarchitectonic atlas of the C57BL/6 and 129/Sv mouse brains
Hof, P. R. (2000) · Elsevier eBooks · Cited by 286
PRZEDBORSKI, S., & VILA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07476.x · Cited by 283
Brain angiotensin receptor subtypes in the control of physiological and behavioral responses
Wright, J. W., & Harding, J. W. (1994) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(94)90034-5 · Cited by 263
Pathophysiology of Parkinson's Disease: The MPTP Primate Model of the Human Disorder
WICHMANN, T., & DeLONG, M. R. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07477.x · Cited by 255 · cited 1×
“Treatment of rodents and non-human primates with neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine [6,7] and rotenone [8] have helped us understand that oxidative stress, mitochondrial respiration dysfunction and protein aggregation are primary mediators of the dopaminergic neu…”
BackgroundWhat?s new in the renin-angiotensin system?: The angiotensin IV/AT4 receptor
Chai, S. Y., Fernando, R., Peck, G., Ye, S. Y., Mendelsohn, F. A. O., Jenkins, T. A., & Albiston, A. L. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4246-1 · Cited by 237 · cited 1×
“In addition, recent studies have also shown a relationship between metabolites of Ang II, such as angiotensin IV, which is believed to be the agonist for the AT4 receptor and is suggested to have a role in memory [24,44-47].”
BackgroundContributions of the Brain Angiotensin IV–AT4Receptor Subtype System to Spatial Learning
Wright, J. W., Stubley, L., Pederson, E. S., Kramár, E. A., Hanesworth, J. M., & Harding, J. W. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-10-03952.1999 · Cited by 182 · cited 1×
“In addition, recent studies have also shown a relationship between metabolites of Ang II, such as angiotensin IV, which is believed to be the agonist for the AT4 receptor and is suggested to have a role in memory [24,44-47].”
BackgroundAngiotensin II-Induced Nuclear Targeting of the Angiotensin Type 1 (AT1) Receptor in Brain Neurons
Lu, D. (1998) · Endocrinology · doi:10.1210/en.139.1.365 · Cited by 178
NADPH Oxidase Contributes to Angiotensin II Signaling in the Nucleus Tractus Solitarius
Wang, G., Anrather, J., Huang, J., Speth, R. C., Pickel, V. M., & Iadecola, C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1176-04.2004 · Cited by 176
Wright, J. W., & Harding, J. W. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.03.003 · Cited by 171 · cited 2×
“In addition, recent studies have also shown a relationship between metabolites of Ang II, such as angiotensin IV, which is believed to be the agonist for the AT4 receptor and is suggested to have a role in memory [24,44-47].”
Backgroundα-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration
Mosharov, E. V., Staal, R. G. W., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M. H., Troyer, M. D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0519-06.2006 · Cited by 165 · cited 1×
“Additional processes that might contribute to susceptibility of DA neurons in PD include: (1) toxicity of tetrahydrobiopterin (an obligatory cofactor for TH) via increased DA production and the cofactor's autooxidation [52] and (2) increasing catecholamine concentrations via overexpression of α-synuclein and resulting…”
BackgroundMazzulli, J. R., Mishizen, A. J., Giasson, B. I., Lynch, D. R., Thomas, S. A., Nakashima, A., Nagatsu, T., Ota, A., & Ischiropoulos, H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0896-06.2006 · Cited by 152 · cited 1×
“Others however argue that elevated DA actually inhibits formation of α-synuclein aggregates [54] and that depletion of DA in vivo does not protect from acute toxicity of MPTP [55].”
BackgroundAhmadi, F. A., Linseman, D. A., Grammatopoulos, T. N., Jones, S. M., Bouchard, R. J., Freed, C. R., Heidenreich, K. A., & Zawada, W. M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02068.x · Cited by 127 · cited 1×
“After 6 days of growth, primary VM cultures consist of approximately 55% neurons, 45% type 1 astrocytes and <1% other cell types, as determined by immunohistochemical analysis [50].”
MethodSelf-citationChronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats
Groth, W., Blume, A., Gohlke, P., Unger, T., & Čulman, J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00028 · Cited by 113 · cited 1×
“Several recent studies have shown that peripheral treatment with AT1 receptor antagonists is protective against ischemia and reduce the cortical volume of the ischemic lesion [36,37].”
BackgroundLopez‐Real, A., Rey, P., Soto‐Otero, R., Mendez‐Alvarez, E., & Labandeira‐Garcia, J. L. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20598 · Cited by 106
Srivastava, R., Brouillet, E., Beal, M. F., Storey, E., & Hyman, B. T. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90114-q · Cited by 103 · cited 1×
“THimmunoreactive SNpc neurons were estimated using an unbiased stereological method according to the optical fractionator principle [59-61] using a Leica DMRB microscope with motorized stage running BioQuant Nova Prime Revision 3.”
MethodGe, J., & Barnes, N. M. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00762-8 · Cited by 102 · cited 3×
“In addition, postmortem studies have shown the loss of both AT1 and AT2 receptor binding sites from the SN in PD patients, suggesting that PD-induced neurodegeneration may involve AT receptor expressing cells [18].”
BackgroundLou, M., Blume, A., Zhao, Y., Gohlke, P., Deuschl, G., Herdegen, T., & Čulman, J. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200405000-00008 · Cited by 97
Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases.
Inagami, T., Eguchi, S., Numaguchi, K., Motley, E. D., Tang, H., Matsumoto, T., & Yamakawa, T. (1999) · PubMed · Cited by 89
Pederson, E. S., Krishnan, R., Harding, J. W., & Wright, J. W. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00312-3 · Cited by 83 · cited 1×
“In addition, recent studies have also shown a relationship between metabolites of Ang II, such as angiotensin IV, which is believed to be the agonist for the AT4 receptor and is suggested to have a role in memory [24,44-47].”
BackgroundCentral Nervous System Blockade by Peripheral Administration of AT1 Receptor Blockers
Wang, J. M., Tan, J., & Leenen, F. H. H. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200304000-00012 · Cited by 80 · cited 2×
“Activation of the AT1 receptor can lead to upregulation of NADPH oxidase, a mechanism for generation of superoxide and elevation of oxidative stress [51].”
BackgroundRodriguez‐Pallares, J., Quiroz, C. R., Parga, J. A., Guerra, M. J., & Labandeira‐Garcia, J. L. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03621.x · Cited by 62 · cited 2×
“A recent observation by Rodriguez-Pallares et al [31] describes that developing rat DA neurons derived from E14 VM express the AT2 receptor.”
BackgroundOlanow, C. W., & Jankovic, J. J. (2005) · Movement Disorders · doi:10.1002/mds.20457 · Cited by 62 · cited 1×
“Several clinical studies have promised the development of new therapies for prevention of dopaminergic neurodegeneration, such as through the use of resagiline, co-enzyme Q10, memantine and others [10].”
BackgroundDavis, C. J., Kramár, E. A., De, A., Meighan, P. C., Simasko, S. M., Wright, J. W., & Harding, J. W. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.051 · Cited by 61 · cited 1×
“In addition, recent studies have also shown a relationship between metabolites of Ang II, such as angiotensin IV, which is believed to be the agonist for the AT4 receptor and is suggested to have a role in memory [24,44-47].”
BackgroundPrasad, K. N., Carvalho, É., Kentroti, S., Edwards‐Prasad, J., Freed, C. R., & Vernadakis, A. (1994) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/bf02631258 · Cited by 60
Parkinson's disease risk factors: genetic, environmental, or both?
Allam, M. F., del Castillo, A. S., & Navajas, R. F. (2005) · Neurological Research · doi:10.1179/016164105x22057 · Cited by 58 · cited 1×
“Insights into the mechanisms responsible for PD have come from epidemiological studies and through animal models of DA neurodegeneration [3-5].”
BackgroundSerum Angiotensin-Converting Enzyme in Multiple Sclerosis
Constantinescu, C. S., Goodman, D. B. P., Grossman, R. I., Mannon, L. J., & Cohen, J. A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550200068012 · Cited by 55 · cited 1×
“Recently, increased attention has focused on understanding the role of the brain-RAS in stroke and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis [17-24].”
BackgroundThe Brain Renin-Angiotensin System: Molecular Mechanisms of Cell to Cell Interactions
Lippoldt, A., Paul, M., Fuxé, K., & Ganten, D. (1995) · Clinical and Experimental Hypertension · doi:10.3109/10641969509087069 · Cited by 53 · cited 1×
“Only recently has it been discovered that all the required components of the RAS, such as renin, angiotensinogen, angiotensin converting enzyme (ACE), angiotensin II (Ang II) and the Ang II (AT) receptors, are present in the mammalian brain [13,14].”
BackgroundEffect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice
Kurosaki, R., Muramatsu, Y., Kato, H., Watanabe, Y., Imai, Y., Itoyama, Y., & Araki, T. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.05.007 · Cited by 49 · cited 2×
“More direct evidence for a role of the brain-RAS in PD comes from studies examining the neuroprotective effects of ACE inhibitors in 6hydroxydopamine and MPTP-induced neurotoxicity rodent models [32-35].”
BackgroundGenetic Analysis of Vascular Factors in Alzheimer's Disease
WAKUTANI, Y., KOWA, H., KUSUMI, M., YAMAGATA, K., WADA‐ISOE, K., ADACHI, Y., TAKESHIMA, T., URAKAMI, K., & NAKASHIMA, K. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04820.x · Cited by 45 · cited 1×
“Recently, increased attention has focused on understanding the role of the brain-RAS in stroke and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis [17-24].”
BackgroundLin, J.-J., Yueh, K.-C., Chang, D., & Lin, S. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00081-3 · Cited by 43 · cited 2×
“One genetic study, suggests that polymorphisms in the gene encoding for ACE may be a risk factor for PD [25].”
BackgroundAngiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death
Grammatopoulos, T. N., Ahmadi, F. A., Jones, S. M., Fariss, M. W., Weyhenmeyer, J. A., & Zawada, W. M. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.038 · Cited by 41
Self-citationLee, S. Y., Moon, Y., Hee Choi, D., Jin Choi, H., & Hwang, O. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.024 · Cited by 40
Are angiotensin receptor blockers neuroprotective?
Thöne‐Reineke, C., Zimmermann, M., Neumann, C., Krikov, M., Li, J., Gerova, N., & Unger, T. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0019-3 · Cited by 38 · cited 1×
“Recently, increased attention has focused on understanding the role of the brain-RAS in stroke and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis [17-24].”
BackgroundARMANDO, I., JEZOVA, M., BREGONZIO, C., BAIARDI, G., & SAAVEDRA, J. M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.036 · Cited by 38 · cited 3×
“In addition, the AT1 receptor has been shown to induce an upregulation of TH, which may result in higher levels of DA [26-28].”
BackgroundHasbani, D. M., Perez, F. A., Palmiter, R. D., & O’Malley, K. L. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0130-05.2005 · Cited by 36 · cited 1×
“Others however argue that elevated DA actually inhibits formation of α-synuclein aggregates [54] and that depletion of DA in vivo does not protect from acute toxicity of MPTP [ 55 ].”
BackgroundKōyama, Y., Egawa, H., Osakada, M., Baba, A., & Matsuda, T. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.023 · Cited by 32 · cited 1×
“In support of the indirect theory, astrocytes are known to produce factors such as glial cell line-derived neurotrophic factor (GDNF) and mesencephalic astrocytes-derived neurotrophic factor (MANF), two highly potent neurotrophic factors for DA neurons [40,41].”
BackgroundGrammatopoulos, T. N., Johnson, V., Moore, S., Andres, R. D., & Weyhenmeyer, J. A. (2004) · Neuroscience Research · doi:10.1016/j.neures.2004.07.010 · Cited by 28 · cited 2×
“The beneficial attributes of the AT2 receptor can be seen in studies describing how the AT2 receptor counteracts the actions of the AT1 receptor by means of its downstream signaling cascades or provide neuroprotection against mitochondrial toxins when unopposed by the AT1 receptor through the use of specific receptor…”
BackgroundSelf-citationGrammatopoulos, T. N., Morris, K. S., FERGUSON, P. W., & Weyhenmeyer, J. A. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00101-8 · Cited by 28 · cited 5×
“We have recently demonstrated that Ang II, through the actions of the AT2 receptor, protects primary cortical neuronal cultures from hypoxic injury [19,38].”
BackgroundMethodSelf-citationGrammatopoulos, T. N., Morris, K. S., Bachar, C., Moore, S., Andres, R. D., & Weyhenmeyer, J. A. (2003) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2003.09.018 · Cited by 25 · cited 2×
“We have recently demonstrated that Ang II, through the actions of the AT2 receptor, protects primary cortical neuronal cultures from hypoxic injury [19, 38 ].”
BackgroundSelf-citationMa, F. Y., Grattan, D. R., Bobrovskaya, L., Dunkley, P. R., & Bunn, S. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02492.x · Cited by 25 · cited 3×
“In addition, the AT1 receptor has been shown to induce an upregulation of TH, which may result in higher levels of DA [26-28].”
BackgroundHanania, T., & Zahniser, N. R. (2002) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02558.x · Cited by 25
Inhibiting Renin-Angiotensin in the Brain: the Possible Therapeutic Implications
Unger, T. (2001) · Blood Pressure · doi:10.1080/080370501750066453 · Cited by 23 · cited 2×
“While we are actively investigating the role of the brain-RAS in PD, the angiotensin system may have a role in other neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, and Huntington's disease [22,48].”
BackgroundGlass, M. J., Huang, J., Speth, R. C., Iadecola, C., & Pickel, V. M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.08.057 · Cited by 20 · cited 3×
“In addition, the AT1 receptor has been shown to induce an upregulation of TH, which may result in higher levels of DA [26-28].”
BackgroundKurosaki, R., Muramatsu, Y., Imai, Y., Kato, H., & Araki, T. (2004) · Neurological Research · doi:10.1179/016164104225015949 · Cited by 16 · cited 2×
“More direct evidence for a role of the brain-RAS in PD comes from studies examining the neuroprotective effects of ACE inhibitors in 6hydroxydopamine and MPTP-induced neurotoxicity rodent models [32-35].”
Background
Cited by
Biomarkers of Oxidative Stress and Antioxidant Defense
Demirci-Çekiç, S., Özkan, G., Avan, A. N., Uzunboy, S., Çapanoğlu, E., & Apak, R. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114477 · Cited by 587
Molecular Mechanisms and Clinical Implications of Reversible Protein S -Glutathionylation
Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A., & Shelton, M. D. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2089 · Cited by 523
Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer
Kayed, R., Pensalfini, A., Margol, L., Sokolov, Y., Sarsoza, F., Head, E., Hall, J., & Glabe, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808591200 · Cited by 348
Tomic, J. L., Pensalfini, A., Head, E., & Glabe, C. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.024 · Cited by 336
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303
Metadata
- Authors
- Grammatopoulos, T. N., Jones, S. M., Ahmadi, F. A., Hoover, B. R., Snell, L. D., Skoch, J., Jhaveri, V. V., Poczobutt, A. M., Weyhenmeyer, J. A., & Zawada, W. M.
- Venue
- Molecular Neurodegeneration
- Published
- 2007-01-15
- Volume
- 2
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1750-1326 (ISSN-L)
- OpenAlex
- W1559076889
- Cited by
- 165
- References
- 61
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.